



(86) Date de dépôt PCT/PCT Filing Date: 2000/11/24
(87) Date publication PCT/PCT Publication Date: 2001/06/07
(85) Entrée phase nationale/National Entry: 2001/07/30
(86) N° demande PCT/PCT Application No.: JP 00/08321
(87) N° publication PCT/PCT Publication No.: WO 01/40450
(30) Priorité/Priority: 1999/12/03 (11/345541) JP

(51) Cl.Int.⁷/Int.Cl.⁷ C12N 9/02, C12P 7/62, C12N 15/53,
C12N 1/21, C12N 9/04

(71) Demandeur/Applicant:
KANEKA CORPORATION, JP

(72) Inventeurs/Inventors:
HASEGAWA, JUNZO, JP;
YASOHARA, YOSHIHIKO, JP;
YAMADA, YUKIO, JP;
KIZAKI, NORIYUKI, JP

(74) Agent: DEETH WILLIAMS WALL LLP

(54) Titre : NOUVELLE CARBONYL REDUCTASE, SON GENE ET SON PROCEDE D'UTILISATION
(54) Title: NOVEL CARBONYL REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME

(57) **Abrégé/Abstract:**

A novel polypeptide capable of forming tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate; and a polynucleotide encoding the same. Namely, a polypeptide which has an enzymatic activity of assymmetrically reducing tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to give tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate and contains the amino acid sequence represented by SEQ ID NO:1 in Sequence Listing or an amino acid sequence derived from the above amino acid sequence by the substitution, insertion, deletion or addition of at lease one amino acid.



(12)特許協力条約に基づいて公開された国際出願

(19) 世界知的所有権機関
国際事務局(43) 国際公開日
2001 年 6 月 7 日 (07.06.2001)

PCT

(10) 国際公開番号
WO 01/40450 A1

- (51) 国際特許分類⁷: C12N 9/02, 大日東町12-11-403 Osaka (JP). 山田勇喜雄 (YAMADA, Yukio) [JP/JP]; 〒675-0334 兵庫県加古川市志方町成井368-7 Hyogo (JP). 八十原良彦 (YASOHARA, Yoshihiko) [JP/JP]; 〒670-0942 兵庫県姫路市日出町3-7-2-605 Hyogo (JP). 長谷川淳三 (HASEGAWA, Junzo) [JP/JP]; 〒674-0057 兵庫県明石市大久保町高丘2-13-4 Hyogo (JP).
- (21) 国際出願番号: PCT/JP00/08321
- (22) 国際出願日: 2000 年 11 月 24 日 (24.11.2000)
- (25) 国際出願の言語: 日本語
- (26) 国際公開の言語: 日本語
- (30) 優先権データ: 特願平11/345541 1999 年 12 月 3 日 (03.12.1999) JP
- (71) 出願人 (米国を除く全ての指定国について): 鐘淵化学工業株式会社 (KANEKA CORPORATION) [JP/JP]; 〒530-0005 大阪府大阪市北区中之島三丁目2番4号 Osaka (JP).
- (72) 発明者; および
- (75) 発明者/出願人 (米国についてのみ): 木崎憲之 (KIZAKI, Noriyuki) [JP/JP]; 〒570-0016 大阪府守口市
- (81) 指定国 (国内): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) 指定国 (広域): ARIPO 特許 (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), ユーラシア特許 (AM,

[続葉有]

(54) Title: NOVEL CARBONYL REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME

(54) 発明の名称: 新規カルボニル還元酵素、その遺伝子、およびその利用法

(57) Abstract: A novel polypeptide capable of forming tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate; and a polynucleotide encoding the same. Namely, a polypeptide which has an enzymatic activity of assymetrically reducing tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to give tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate and contains the amino acid sequence represented by SEQ ID NO:1 in Sequence Listing or an amino acid sequence derived from the above amino acid sequence by the substitution, insertion, deletion or addition of at lease one amino acid.

(57) 要約:

(3 R, 5 S) - 6 - クロロ - 3, 5 - ジヒドロキシヘキサン酸 t e r t - ブチルを生成する新規ポリペプチド、それをコードするポリヌクレオチドおよびその利用方法を提供する。(S) - 6 - クロロ - 5 - ヒドロキシ - 3 - オキソヘキサン酸 t e r t - ブチルを不斉的に還元して (3 R, 5 S) - 6 - クロロ - 3, 5 - ジヒドロキシヘキサン酸 t e r t - ブチルを生成する酵素活性を有するポリペプチドであって、配列表の配列番号 1 に示したアミノ酸配列、または配列表の配列番号 1 に示したアミノ酸配列中で少なくとも 1 つのアミノ酸の置換、挿入、欠失または付加を有するアミノ酸配列を含む、ポリペプチドが提供される。

WO 01/40450 A1

WO 01/40450 A1



AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ特許 (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI 特許 (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

添付公開書類:
— 国際調査報告書

- 請求の範囲の補正の期限前の公開であり、補正書受領の際には再公開される。
- 明細書とは別に規則 13 の 2 に基づいて提出された生物材料の寄託に関する表示。

2 文字コード及び他の略語については、定期発行される各 *PCT* ガゼットの巻頭に掲載されている「コードと略語のガイダンスノート」を参照。

DESCRIPTION

NOVEL CARBONYL REDUCTASE, GENE THEREOF AND METHOD OF USING
THE SAME

5

TECHNICAL FIELD

The present invention relates to a novel polypeptide,
a gene encoding the polypeptide, an expression vector for
10 expressing the polypeptide, a transformant obtained by
transforming a host cell using the expression vector, and
a method for producing a compound useful as a material for
synthesis of medicaments and pesticides using the
transformant. More particularly, the present invention
15 relates to a polypeptide isolated from a microorganism
having an enzyme activity to asymmetrically reduce
tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to
tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate, a
polynucleotide encoding the polypeptide, an expression
20 vector including the polynucleotide, and a transformant
transformed by the expression vector.

The present invention also relates to a method for
producing tert-butyl (3R,5S)-6-chloro-3,5-
25 dihydroxyhexanoate. The method includes the steps of
reacting the transformant or a processed product thereof
with tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate,
and collecting the produced tert-butyl (3R,5S)-6-
chloro-3,5-dihydroxyhexanoate.

30

Tert-butyl (3R,5S)-6-chloro-3,5-
dihydroxyhexanoate is a compound useful as a material for
synthesis of medicaments and pesticides, particularly

HMG-CoA reductase inhibitors.

BACKGROUND ART

5 The only method for producing tert-butyl
(3R,5S)-6-chloro-3,5-dihydroxyhexanoate by asymmetrically
reducing tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate,
which has been reported, employs diethylmethoxyborane and
sodium borohydride (U.S. Patent No. 52,783,131). Problems
10 with this technique are that a very low temperature reaction
vessel achieving temperatures as low as -78°C is required,
that expensive materials need to be employed, and the like.
There has been a demand for a practical reaction procedure.

15 DISCLOSURE OF THE INVENTION

 The inventors of the present invention found a
polypeptide derived from a microorganism which
asymmetrically reduces tert-butyl (S)-6-chloro-5-
20 hydroxy-3-oxohexanoate to produce tert-butyl (3R,5S)-6-
chloro-3,5-dihydroxyhexanoate, envisioned a method which
can efficiently produce tert-butyl (3R,5S)-6-chloro-
3,5-dihydroxyhexanoate, and eventually achieved the
present invention.

25 An objective of the present invention is to provide
a polypeptide capable of asymmetrically reducing tert-butyl
(S)-6-chloro-5-hydroxy-3-oxohexanoate to produce tert-
butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate. Another
30 objective of the present invention is to provide a method
for efficiently producing the polypeptide using recombinant
DNA technology. Still another objective of the present
invention is to provide a transformant which can produce

said polypeptide, and a polypeptide having a glucose dehydrogenase activity, simultaneously to a large extent. Even still another objective of the present invention is to provide a practical method for producing tert-butyl
5 (3R,5S)-6-chloro-3,5-dihydroxyhexanoate using the transformant.

The present invention relates to a polypeptide having an enzyme activity to asymmetrically reduce
10 tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate. The polypeptide comprises the amino acid sequence represented by SEQ ID NO. 1 in the Sequence Listing, or the amino acid sequence having at least one amino acid substitution,
15 insertion, deletion, or addition thereof.

Preferably, the peptide may be derived from a microorganism belonging to genus *Candida*. More preferably, the microorganism may be *Candida magnoliae* IFO 0705.
20

In one aspect, the present invention relates to a polynucleotide encoding the above-described polypeptide.

In one aspect, the present invention relates to a
25 polynucleotide encoding a polypeptide having an enzyme activity to asymmetrically reduce tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate. The polynucleotide is hybridized with a nucleotide sequence represented by SEQ
30 ID NO. 2 in the Sequence Listing under stringent conditions.

In one aspect, the present invention relates to an expression vector including the above-described

polynucleotide. Preferably, the expression vector may be plasmid pNTCR.

5 In one embodiment, the above-described expression vector may further include a polynucleotide encoding a polypeptide having a glucose dehydrogenase activity.

10 Preferably, the polypeptide having a glucose dehydrogenase activity may be a glucose dehydrogenase derived from *Bacillus megaterium*.

Preferably, the expression vector may be plasmid pNTCRG.

15 In one aspect, the present invention relates to a transformant obtained by transforming a host cell using the above-described expression vector.

20 Preferably, the host cell may be *Escherichia coli*. More preferably, the transformant may be *E. coli* HB101 (pNTCR) or *E. coli* HB101 (pNTCRG).

25 In one aspect, the present invention relates to a method for producing tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate. The method comprises the steps of reacting the above-described transformant and/or a processed product thereof with tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate, and collecting produced tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate.

30

Preferably, the reacting step is carried out in the presence of a coenzyme restoring system.


BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a diagram showing the sequence of a polynucleotide of the present invention, and the predicted amino acid sequence thereof.


Figure 2 is a diagram showing a method for producing the recombinant plasmid pNTCRG.

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the present invention will be described in detail. As a polypeptide of the present invention, any polypeptide may be employed as long as it has an enzyme activity to asymmetrically reduce tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate represented by the following formula (I) to produce tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate represented by the following formula (II).



tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate



30 tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate

Examples of such polypeptides include a polypeptide comprising the amino acid sequence of SEQ ID NO. 1 in the

Sequence Listing and a polypeptide comprising an amino acid sequence having at least one amino acid substitution, insertion, deletion, or addition, or a part thereof, and having an enzyme activity to asymmetrically reduce
5 tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to
produce tert-butyl (3R,5S)-6-chloro-3,5-
dihydroxyhexanoate.

 A polypeptide of the present invention can be
10 obtained from a microorganism having an activity to
asymmetrically reduce tert-butyl (S)-6-chloro-5-
hydroxy-3-oxohexanoate to produce tert-butyl (3R,5S)-6-
chloro-3,5-dihydroxyhexanoate. Therefore, the
microorganism used as a source of the polypeptide may be,
15 not limited to, yeast (genus *Candida*), and most preferably
Candida magnoliae IFO 0705. This strain was a
microorganism deposited originally under the deposit number
CBS166 at Centraalbureau voor Schimmelcultures (CBS;
Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, Netherlands),
20 and the isolation and properties of the strain are described
in "The Yeasts, a Taxonomic Study. 3rd ed. pp. 731 (1984)".
Microorganisms producing polypeptides of the present
invention may be of a wild type or variant type strain.
Alternatively, microorganisms genetically engineered
25 (using cell fusion, gene manipulation, etc.) may be employed.
Microorganisms genetically engineered to produce peptides
of the present invention can be obtained by a method
including the steps of: isolating and/or purifying these
enzymes and determining the entire or partial amino acid
30 sequence thereof; determining nucleotide sequences
encoding the polypeptides based on the amino acid sequences
thereof; obtaining nucleotide sequences encoding the
polypeptides based on the amino acid sequences thereof;

introducing the nucleotide sequences into other microorganisms to obtain recombinant microorganisms; and cultivating the recombinant microorganisms to obtain enzymes of the present invention.

5

A culture medium for microorganisms producing polypeptides of the present invention may be any liquid nutrient medium containing a typical carbon source, nitrogen source, mineral salt source, organic nutrient source, and the like as long as the microorganisms can grow.

10

The term "microorganism culture" as used herein refers to a microorganism itself or a liquid culture containing the microorganism, and "its processed product" refers to a product obtained by extraction or purification of the microorganism itself or the liquid culture containing the microorganism.

15

Polypeptides of the present invention can be purified from microorganisms containing the polypeptides using a conventional method. For example, a microorganism is cultivated in an appropriate medium, and the culture is centrifuged to harvest the microorganism. The microorganism is disrupted by Dyno mill (manufactured by Willy A. Bachofen Co., Ltd.), for example, and centrifuged to remove cell debris and thus obtain a cell-free extract. The cell-free extract is then subjected to techniques, such as salting-out (e.g., ammonium sulfate precipitation and sodium phosphate precipitation), solvent precipitation (a protein fractionation precipitation method using acetone, ethanol, or the like), dialysis, gel filtration, ion exchange, column chromatography (e.g., reverse phase chromatography), and ultrafiltration, alone or in

20

25

30

combination, to purify the polypeptides. Enzyme activity can be determined by measuring the reduction in absorption at a wavelength of 340 nm at 30°C where 5 mM tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate as a substrate, 5 0.33 mM NADPH as a coenzyme, and an enzyme are added to a 100 mM phosphate buffer (pH 6.5).

Polypeptides of the present invention may include the amino acid sequence of SEQ ID NO. 1 in the Sequence Listing. Polypeptides having an amino acid sequence having at least one amino acid substitution, insertion, deletion, or addition, or a part thereof, and having an enzyme activity to asymmetrically reduce tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to produce tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate can be prepared from a 15 polypeptide having the amino acid sequence of SEQ ID NO. 1 in the Sequence Listing using a known method described in Current Protocols in Molecular Biology (John Wiley and Sons, Inc., 1989), or the like. Any polypeptide falls within the 20 scope of the present invention as long as it has the enzyme activity to asymmetrically reduce tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate.

25 Polynucleotides of the present invention may be any polynucleotide encoding any one of the above-described polypeptides. An example of a polynucleotide of the present invention is a polynucleotide having the nucleotide sequence of SEQ ID NO. 2 in the Sequence Listing, and a 30 polynucleotide capable of being hybridized with that polynucleotide under stringent conditions.

The polynucleotide capable of being hybridized with

the polynucleotide having the nucleotide sequence of SEQ ID NO. 2 in the Sequence Listing under stringent conditions means a polynucleotide obtained with a colony hybridization method, a plaque hybridization method, a southern hybridization method or the like when the nucleotide sequence of SEQ ID No.2 is used as a DNA probe. Specifically, the polynucleotide can be identified as follows. A filter on which polynucleotides derived from a colony or plaque are immobilized is subjected to hybridization with the nucleotide sequence of SEQ ID No.2 in 0.7 to 1.0 M NaCl at 65°C, and thereafter the filter is washed with an SSC solution having 0.1 to 2-fold concentration (one-fold concentration SSC solution contains 150 mM sodium chloride and 15 mM sodium citrate) at 65°C.

15

Hybridization may be carried out in accordance with a procedure described in Molecular Cloning, A laboratory manual, second edition (Cold Spring Harbor Laboratory Press, 1989), or the like. Specifically, examples of a polynucleotide capable of the above-described hybridization include a polynucleotide having at least 60% sequence identity with the nucleotide sequence of SEQ ID NO. 2, preferably at least 80% sequence identity, more preferably at least 90% sequence identity, even more preferably at least 95% sequence identity, and most preferably at least 99% sequence identity.

25

Polynucleotides of the present invention encoding polypeptides having the enzyme activity to asymmetrically reduce tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate include a polynucleotide having at least 60% sequence identity with the nucleotide sequence of SEQ ID NO. 2,

30

preferably at least 80% sequence identity, more preferably at least 90% sequence identity, even more preferably at least 95% sequence identity, and most preferably at least 99% sequence identity, as long as the encoded polypeptides have the above-described enzyme activity. The term "sequence identity" means that two polynucleotide sequences to be compared are identical to each other, and the rate (%) of sequence identity between two polynucleotides to be compared is calculated as follows. First, two polynucleotide sequences to be compared are aligned in an optimal manner. The number of sites at which the same nucleic-acid base (e.g., A,T,C,G,U, or I) is present on both sequences (the number of matched sites) is counted and the number of matched sites is divided by the total number of nucleic-acid bases in the polynucleotide. The resultant value is multiplied by 100. Sequence identity can be calculated using the following sequence analyzing tool, for example: Unix-based GCG Wisconsin Package (Program Manual for the Wisconsin Package, Version 8, September, 1994, Genetics Computer Group, 575 Science Drive Madison, Wisconsin, USA53711; Rice P. (1996) Program Manual for EGCG Package, Peter Rice, The Sanger Centre, Hinxton Hall, Cambridge, CB10 1RQ, England) and the ExpASY World Wide Web server for molecular biology (Geneva University Hospital and University of Geneva, Geneva, Switzerland).

Polynucleotides of the present invention can be obtained from microorganisms having the enzyme activity to asymmetrically reduce tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate. The microorganism used as a source of the polynucleotide may be, not limited to, yeast (genus *Candida*), and most preferably *Candida magnoliae* IFO 0705.

Hereinafter, a method for producing a polynucleotide of the present invention from microorganisms having the enzyme activity to asymmetrically reduce
5 tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate will be described. The present invention is not limited to this.

Initially, the amino acid sequences of the purified
10 polypeptide, and peptide fragments obtained by digesting the polypeptide with an appropriate endopeptidase are sequenced by the Edman method. Based on this amino acid sequence information, a nucleotide primer is synthesized. Thereafter, chromosomal DNA is prepared from a
15 microorganism, from which the polynucleotide is originated, using a typical nucleotide isolation method (e.g., Hereford method described in Cell, 18, 1261 (1979)). PCR is carried out using the above-described nucleotide primer and this chromosomal DNA as a template to amplify a part of the
20 polypeptide gene. Further, the amplified part of the polypeptide gene is labeled with a random primer labeling method described in Anal. Biochem., 132, 6 (1983), for example, to prepare a nucleotide probe. The chromosomal DNA of the microorganism is digested by an appropriate
25 restriction enzyme. The resultant fragments are incorporated into a vector which is in turn introduced into an appropriate host cell, thereby constructing a DNA library of chromosomal DNA of the microorganism. This DNA library is screened using the above-described nucleotide probe in
30 accordance with a colony hybridization method, a plaque hybridization method, or the like, thereby obtaining DNA including the polypeptide gene. The nucleotide sequence of the thus-obtained DNA fragment including the polypeptide

gene can be sequenced with a dideoxy sequencing method, a dideoxy chain termination method, or the like. For example, the sequencing of the nucleotide sequence may be carried out using ABI PRISM Dye Terminator Cycle Sequencing Ready
5 Reaction Kit (manufactured by Perkin Elmer Co., Ltd.) and ABI 373A DNA Sequencer (manufactured by Perkin Elmer Co., Ltd.).

Vectors for introducing polynucleotides of the present invention into host microorganisms, in which the polynucleotides are expressed, may be any vector as long as the enzyme gene can be expressed in the appropriate host microorganisms. Examples of such vectors include a plasmid vector, a phage vector, and a cosmid vector. A shuttle
10 vector may be used that can exchange a gene between host strains. Such a vector typically includes a control element, such as a lacUV5 promoter, a trp promoter, a trc promoter, a tac promoter, a lpp promoter, a tufB promoter, a recA promoter, or a pL promoter, and is preferably employed
15 as an expression vector including an expression unit operatively linked to the polynucleotide of the present invention.
20

The term "control element" as used herein refers to a functional promoter and a nucleotide sequence having any associated transcription element (e.g., enhancer, CCAAT box, TATA box, SPI site).
25

The phrase "operatively linked" as used herein refers to that a polynucleotide is linked with controlling elements, such as a promoter and an enhancer, which control expression of the polynucleotide in such a manner that the controlling elements can operate to express the gene. It
30

is well known to those skilled in the art that the types of control elements may vary depending on the host cell.

5 Examples of host cells, into which a vector having a polynucleotide of the present invention is introduced, include bacteria, yeast, molds, plant cells, and animal cells. *Escherichia coli* is particularly preferable. A polynucleotide of the present invention can be introduced into a host cell using a conventional method. When *E. coli* 10 is used as a host cell, a polynucleotide of the present invention can be introduced using a calcium chloride method, for example.

15 When producing tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate by asymmetrically reducing tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate using a polypeptide of the present invention, a coenzyme, such as NADPH and NADH, is required. However, an enzyme capable of transforming an oxidized coenzyme to a reduced coenzyme (hereinafter 20 referred to as coenzyme restoring capability) can be used along with a corresponding substrate, i.e., a coenzyme restoring system is used in combination with a polypeptide of the present invention in reaction, thereby reducing the quantity of expensive coenzyme used. Examples of enzymes 25 having coenzyme restoring capability include hydrogenase, formate dehydrogenase, alcohol dehydrogenase, aldehyde dehydrogenase, glucose-6-phosphate dehydrogenase, and glucose dehydrogenase. Preferably, glucose dehydrogenase is used. Such a reaction may be carried out by adding a 30 coenzyme restoring system to an asymmetric reaction system. When using, as a catalyst, a transformant transformed both with a polynucleotide encoding a polypeptide having the enzyme activity to asymmetrically reduce tert-butyl

(S)-6-chloro-5-hydroxy-3-oxohexanoate to produce tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate, and a polynucleotide encoding a polypeptide having a glucose dehydrogenase activity, the reactions can be efficiently carried out without preparing an enzyme having the coenzyme restoring capability and adding the enzyme to a reaction system. Such a transformant can be obtained by incorporating a polynucleotide encoding a polypeptide having the enzyme activity to asymmetrically reduce tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to produce tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate, and a polynucleotide encoding a polypeptide having a glucose dehydrogenase activity, into the same vector, and introducing the vector into a host cell. Alternatively, the transformant can be obtained by incorporating these two polynucleotides into two vectors derived from incompatible groups, and introducing these polynucleotides into the same host cell.

Glucose dehydrogenase activity of the transformant can be determined by measuring an increase in absorption at a wavelength of 340 nm at 25°C where 0.1 M glucose as a substrate, 2 mM NADP as a coenzyme, and an enzyme are added to a 1 M Tris HCl buffer (pH 8.0).

Production of tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate using a transformant of the present invention may be carried out as follows.

Initially, tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate as a substrate, a coenzyme such as NADP, and the culture of the transformant or a processed product thereof are added to an appropriate solvent, followed by

KA024PCT

pH adjustment. The resultant mixture is stirred to be reacted. The reaction is carried out at a temperature of 10°C to 70°C while maintaining the pH of the reaction solution in the range of 4 to 10. The reaction is carried out in a batch process or a continuous process. In the case of a batch process, a substrate to be reacted is added to prepare a concentration of 0.1% to 70% (w/v). The processed product of a transformant and the like mentioned above refers to a crude extract, cultured microorganisms, lyophilized organisms, acetone dried organisms, homogenates of such microorganisms, and the like. Such processed products and the like may be used in the state of being immobilized as enzymes or microorganisms as they are, by a known means. When the reaction is carried out using a transformant which produces a polypeptide of the present invention and a glucose dehydrogenase, addition of glucose to the reaction system allows a reduction in the quantity of coenzymes to a large extent.

20 Tert-butyl (3R,5S)-6-chloro-3,5-
dihydroxyhexanoate produced by the reaction can be purified
by a conventional method. For example, tert-butyl
(3R,5S)-6-chloro-3,5-dihydroxyhexanoate is subjected to
centrifugation, filtration and other processes as required
25 to remove suspending substances such as microorganisms.
The resultant product is subjected to extraction with an
organic solvent such as ethyl acetate and toluene, and
dehydrated with a dehydrant such as sodium sulfate. The
organic solvent is removed under decompression. The
30 resultant product is then subjected to crystallization,
chromatography, or the like to be purified.

In the reaction, tert-butyl (S)-6-chloro-5-

hydroxy-3-oxohexanoate as a substrate is prepared with a method described in U.S. Patent No.52,783,131 which is herein incorporated by reference.

5 Quantification of tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate and tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate, and measurement of the diastereomer ratio of tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate can be performed by high performance
10 liquid chromatography (column: COSMOSIL 5CN-R (ID 4.6 x 250 mm) manufactured by Nacalai Tesque Co., Ltd., eluant: 1 mM phosphate solution/acetonitrile = 5/1, flow rate: 0.7 ml/min, detection: 210 nm, column temperature: 30°C).

15 As described above, according to the present invention, it is possible to efficiently produce a polypeptide of the present invention. With such a polypeptide, an excellent method for producing tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate can be provided.
20 Hereinafter, the present invention will be described by way of illustrative examples with reference to the accompanying drawings. The present invention is not limited to such examples.

25 (Examples)

The details of manipulation methods relating to recombinant DNA techniques employed in the following examples are described in the following texts.

30 Molecular Cloning 2nd Edition(Cold Spring Harbor Laboratory Press,1989)

Current Protocols in Molecular Biology(Greene Publishing

Associates and Wiley-Interscience)

(Example 1: Purification of a Polypeptide having Asymmetrical Reduction Enzyme Activity)

5 From *Candida magnoliae* IFO 0705, a polypeptide having the enzyme activity to asymmetrically reduce tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate is purified singly in the following manner.

10

(Cultivation of *Candida magnoliae* IFO 0705)

18 l of liquid medium having the following composition was prepared in a 30 l jar fermenter (manufactured by Marubishi Bioeng Co., Ltd.), and
15 sterilized with steam at 120°C for 20 minutes.

Composition of medium: tap water, glucose 4.0%, yeast extract 0.5%, KH_2PO_4 0.1%, $(\text{NH}_4)_2\text{HPO}_4$ 0.65%, NaCl 0.1%, $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ 0.8%, $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ 0.06%, $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ 0.09%, $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$
20 0.005%, $\text{MnSO}_4 \cdot 4-6\text{H}_2\text{O}$ 0.01%, and Adecanol™ LG-109 (Manufactured by NOF Corporation) 0.02% (pH 7.0).

The above medium was inoculated with a culture of *Candida magnoliae* IFO 0705, which had been pre-cultured in
25 the medium, by 180 ml/fermenter and cultured at 33°C with agitation at 295 rpm at an aeration rate of 5.0 NL/min while maintaining the lower limit of pH at 6.5 by dripping 30% (w/w) aqueous sodium hydroxide. 655 g of 55% (w/w) aqueous glucose solution was added 22 hours and 25 hours after the
30 start of the cultivation. The cultivation was carried out for 30 hours.

(Preparation of Cell-free Extract)

Microorganisms were collected from 10 L of the resultant culture by centrifugation and then washed with a physiological saline solution, thereby obtaining 1350 g of wet microorganisms. The wet microorganisms were suspended in 2700 ml of a 100 mM phosphate buffer (pH 6.7), and 2-mercaptoethanol and phenylmethylsulfonyl fluoride were added to final concentrations of 5 mM and 0.1 mM, respectively. The microorganisms were disrupted by Dyno mill (manufactured by Willy A. Bachofen Co., Ltd.). The disrupted microorganisms were centrifuged to remove cell debris, thereby obtaining 2880 ml of a cell-free extract.

(Ammonium Sulfate Fractionation)

Ammonium sulfate was added to and dissolved in the cell-free extract so as to obtain 60% saturation. The resultant precipitates were removed by centrifugation (in this case, the pH of the cell-free extract was maintained at 6.7 with ammonia water). Ammonium sulfate was further added to the supernatant to obtain 75% saturation while maintaining pH 6.7 similarly. The resultant precipitates were collected by centrifugation. The precipitates were dissolved and dialyzed overnight in 10 mM phosphate buffer (pH 7.0) containing 2 mM 2-mercaptoethanol.

(DEAE-TOYOPEARL Column Chromatography)

The above resultant crude enzyme solution was supplied to a DEAE-TOYOPEARL 650M (500ml; manufactured by Tosoh Corporation) column which had been equilibrated with 10 mM phosphate buffer (pH 7.0) containing 2 mM 2-mercaptoethanol, so that polypeptides having enzyme activity were adsorbed to the column. The column was washed with the same buffer. Active fractions were eluted using a linear gradient of NaCl (from 0 M to 0.5 M). The active

fractions were collected and then dialyzed overnight in 10 mM phosphate buffer (pH 7.0) containing 2 mM 2-mercaptoethanol.

5 (Phenyl Sepharose Column Chromatography)

Ammonium sulfate was dissolved in the above resultant crude enzyme solution to a final concentration of 1 M (while maintaining pH 7.0 with ammonia water), and then supplied to a Phenyl sepharose CL-4B column (140 ml; 10 manufactured by Pharmacia Biotech Co., Ltd.) which had been equilibrated with 10 mM phosphate buffer (pH 7.0) containing 2 mM 2-mercaptoethanol and 1 M ammonium sulfate, so that polypeptides having enzyme activity were adsorbed to the column. The column was washed with the same buffer. 15 Active fractions were eluted using a linear gradient of ammonium sulfate (from 1 M to 0 M). The active fractions were collected and then dialyzed overnight in 10 mM phosphate buffer (pH 7.0) containing 2 mM 2-mercaptoethanol.

20

(Blue Sepharose Column Chromatography)

The above resultant crude enzyme solution was supplied to a Blue sepharose CL-6B column (40ml; manufactured by Pharmacia Biotech Co., Ltd.) which had been 25 equilibrated with 10 mM phosphate buffer (pH 7.0) containing 2 mM 2-mercaptoethanol, so that polypeptides having enzyme activity were adsorbed to the column. The column was washed with the same buffer. Active fractions were eluted using a linear gradient of NaCl (from 0 M to 30 1 M). The active fractions were collected and then dialyzed overnight in 10 mM phosphate buffer (pH 7.0) containing 2 mM 2-mercaptoethanol.

(SuperQ-TOYOPEARL Column Chromatography)

The above resultant crude enzyme solution was supplied to a SuperQ-TOYOPEARL 650S column (12 ml; manufactured by Tosoh Corporation) which had been equilibrated with a 10 mM phosphate buffer (pH 7.0) containing 2 mM 2-mercaptoethanol, so that polypeptides having enzyme activity were adsorbed to the column. The column was washed with the same buffer. Active fractions were eluted using a linear gradient of NaCl (from 0 M to 0.4 M). The active fractions were collected and then dialyzed overnight in a 10 mM phosphate buffer (pH 7.0) containing 2 mM 2-mercaptoethanol. Thus, a pure polypeptide specimen which is electrophoretically single was obtained (hereinafter referred to as a CR enzyme).

15

(Example 2: Cloning of CR enzyme gene)

(Preparation of Synthetic Oligonucleotide Probe)

The purified CR enzyme obtained in Example 1 was denatured in the presence of 8 M urea, and then digested with lysyl endopeptidase derived from *Achromobacter* (manufactured by Wako Pure Chemical Industries, Ltd.). The amino acid sequences of the resultant peptide fragments were determined using ABI492 protein sequencer (manufactured by Perkin Elmer Co., Ltd.). Based on the amino acid sequences, two nucleotide primers (SEQ ID NOs. 3 and 4) were synthesized with a conventional method.

25

(Amplification of CR Enzyme Gene by PCR)

Chromosomal DNA was extracted from cultured *Candida magnoliae* IFO 0705 in accordance with the Hereford method (Cell, 18, 1261 (1979)). Thereafter, PCR was carried out using the above-prepared nucleotide primer and the resultant chromosomal DNA as a template, thereby amplifying

30

a nucleotide fragment of about 350 bp which is considered to be a part of the CR enzyme gene.

(Preparation of Chromosomal DNA Library)

5 The chromosomal DNA of *Candida magnoliae* IFO 0705 was completely digested with restriction enzyme *ApaI*, and the digested fragments were separated with agarose gel electrophoresis. Thereafter, a southern method (J. Mol. Biol., 98, 503 (1975)) was carried out using the 350-bp DNA
10 fragment obtained above to analyze the digested fragments of the chromosomal DNA (the labeling and detection of a nucleotide probe were carried out using Gene Images Labeling and Detection System (manufactured by Amersham Co., Ltd.)). As a result, it was found that a nucleotide fragment of about
15 5.5 kb was hybridized with the nucleotide probe.

Based on this fact, after the digested fragments were separated by agarose gel electrophoresis, nucleotide fragments of 4.3 kb to 6.2 kb were collected. These
20 nucleotide fragments were introduced into the *ApaI* site of plasmid vector pBluescriptII KS(-) (manufactured by STRATAGENE Co., Ltd.). The plasmid was introduced into *E. coli* JM109. The chromosomal DNA library of this strain was prepared.

25

(Screening of Chromosomal DNA Library)

The thus-obtained nucleotide fragment was used as a probe to screen the chromosomal DNA library in accordance with a colony hybridization method (the labeling and
30 detection of a nucleotide probe were carried out using Gene Images Labeling and Detection System (manufactured by Amersham Co., Ltd.)), and the experiment was carried out in accordance with procedures described in the instruction

manual of the system). As a result, a single positive colony was obtained. Thereafter, recombinant plasmids obtained from the positive colony, into which DNA of about 5.5 kb had been inserted, were double digested with EcoRI and SphI. 5 The digested fragments were analyzed with the southern method as described above. As a result, nucleotide fragments of about 1.0 kb produced by the digestion using the restriction enzymes were hybridized with the probe. Based on this fact, the nucleotide fragment of about 1.0 kb 10 was inserted into the EcoRI-SphI site of plasmid pUC19 (manufactured by Takara Shuzo Co., Ltd.) to construct recombinant plasmid pUC-ES and selected as a chromosomal DNA clone including the CR enzyme gene.

15 (Determination of Base Sequence)

The above recombinant plasmid pUC-ES was digested with a variety of restriction enzymes, and digested fragments produced during the reaction were analyzed to prepare a restriction map. Then, various DNA fragments 20 obtained during the analysis were inserted into multi-cloning sites of pUC19, to construct recombinant plasmids. Using these recombinant plasmids, nucleotide sequences of the respective inserted fragments were analyzed using ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit 25 (manufactured by Perkin Elmer Co., Ltd.) and ABI 373A DNA Sequencer (manufactured by Perkin Elmer Co., Ltd.). As a result, the entire base sequence of the DNA fragment of about 1.0 kb which was expected to include an intended enzyme gene was determined. Figure 2 shows the thus-determined base 30 sequence. An amino acid sequence predicted from the nucleotide sequence for the structural gene portion of the nucleotide sequence is also shown under the corresponding nucleotide sequence in Figure 1. The amino acid sequence

was compared with a partial amino acid sequence of a lysyl endopeptidase digested peptide fragment of the purified CR enzyme. As a result, it was found that the partial amino acid sequence of the purified CR enzyme completely exists in the amino acid sequence predicted from the nucleotide sequence and completely matches therewith (indicated as an underlined portion in the amino acid sequence in Figure 1). Therefore, the DNA fragment was considered to include the CR enzyme gene.

(Example 3: Preparation of Recombinant Plasmid Carrying CR Enzyme Gene)

A double-stranded DNA having: an NdeI site added to an initiation codon portion of a structural gene of the CR enzyme; and a new termination codon (TAA) and an EcoRI site added immediately after a termination codon; and T substituted for G at sixth nucleotide from the 5' end of the gene in order to destroy an SalI site of the gene without an amino acid code modification, was obtained in the following manner. An N-terminus nucleotide primer having an NdeI site added to the initiation codon portion of the structural gene of the CR enzyme and T substituted for G at sixth nucleotide from the 5' end of the gene was synthesized based on the nucleotide sequence determined in Example 2. Further, a C-terminus nucleotide primer having the new termination codon (TAA) and an EcoRI site added immediately after the termination codon of the structural gene of the CR enzyme was synthesized based on the nucleotide sequence determined in Example 2. The nucleotide sequences of these two primers are represented by SEQ ID NOs. 5 and 6. Using the two synthetic DNA primers, a double-stranded DNA was amplified by PCR using the plasmid pUC-ES obtained in Example 2 as a template. The resultant DNA fragment was

digested with NdeI and EcoRI, and inserted into NdeI and EcoRI sites downstream from the lac promoter of the plasmid pUCNT (WO94/03613), to obtain recombinant plasmid pNTCR.

5 (Example 4: Production of Recombinant Plasmid including both CR Enzyme Gene and Glucose Dehydrogenase Gene)

 A double-stranded DNA having: a Shine-Dalgarno
sequence (9 nucleotides) of E. coli added 5 nucleotides
10 upstream from the initiation codon of the glucose
dehydrogenase (hereinafter referred to as GDH) gene derived
from Bacillus megaterium IAM 1030; an EcoRI site added
immediately therebefore; and an Sall site immediately after
the termination codon was obtained in the following manner.
15 Based on the nucleotide sequence information on the GDH gene,
an N-terminus nucleotide primer having the Shine-Dalgarno
sequence (9 nucleotides) of E. coli added 5 nucleotides
upstream from the initiation codon of the structural gene
of GDH and the EcoRI site added immediately therebefore,
20 and a C-terminus nucleotide primer having the Sall site added
immediately after the termination codon were synthesized
with a conventional method. The nucleotide sequences of
these two primers are represented by SEQ ID NOs. 7 and 8.
Using the two synthetic DNA primers, a double-stranded DNA
25 was synthesized by PCR using the plasmid pGDK 1(Eur. J.
Biochem. 186, 389 (1989)) as a template. The resultant DNA
fragment was digested with EcoRI and Sall, and inserted into
EcoRI and Sall sites of pNTCR constructed in Example 3
(existing downstream from the CR enzyme gene) to obtain
30 recombinant plasmid pNTCRG. The production method and
structure of pNTCRG are shown in Figure 2.

(Example 5: Preparation of Recombinant E. coli)

E. coli HB101 (manufactured by Takara Shuzo Co., Ltd.) was transformed using recombinant plasmid pNTCR obtained in Example 3 and the recombinant plasmid pNTCRG obtained in Example 4, to obtain recombinant E. coli HB101 (pNTCR) and HB101 (pNTCRG), respectively. The thus-obtained transformants, E. coli HB101 (pNTCR) and HB101 (pNTCRG), were deposited with the Ministry of International Trade and Industry, Agency of Industrial Science and Technology, National Institute of Bioscience and Human Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) under the respective deposit numbers FERM BP-6897 and FERM BP-6898 on September 28, 1999, pursuant to Budapest Treaty of the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure.

(Example 6: Expression of CR Enzyme in Recombinant E. coli)

The recombinant E. coli HB101 (pNTCR) obtained in Example 5 was cultured in 2xYT medium containing 120 µg/ml of ampicillin, collected, suspended in a 100 mM phosphate buffer (pH 6.5), and subjected to ultrasonic treatment, to obtain a cell-free extract. The CR enzyme activity of the cell-free extract was measured in the following manner. That is, 5 mM tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate as a substrate, 0.333 mM NADPH as a coenzyme, and the enzyme were added to a 100 mM phosphate buffer (pH 6.5), and reduction in absorption at a wavelength of 340 nm was measured at 30°C. Under these reaction conditions, oxidation of 1 µmol NADPH into NADP in one minute was defined as one unit of enzyme activity. The thus-measured CR enzyme activity in the cell-free extract was represented as a specific activity and compared with that

of a transformant holding only a vector plasmid. Also, the CR enzyme activity in a cell-free extract of *Candida magnoliae* IFO 0705 prepared in substantially the same manner as that described in Example 1 was compared. The results are shown in Table 1 below.

Table 1 Expression of CR enzyme in Recombinant *E. coli*

Microorganism	CR enzyme specific activity (U/mg)
HB101 (pUCNT)	0.12
HB101 (pNTCR)	3.76
<i>Candida magnoliae</i> IFO 0705	0.11

As is seen from Table 1, *E. coli* HB101 (pNTCR) exhibited a definite increase in CR enzyme activity in comparison with *E. coli* HB101 (pUCNT) which was transformed using only a vector plasmid, and exhibited an activity about 34 times as large as that of *Candida magnoliae* IFO 0705.

(Example 7: Simultaneous Expression of CR Enzyme and GDH in Recombinant *E. coli*)

The GDH activity of a cell-free extract obtained by processing recombinant *E. coli* HB101 (pNTCRG) obtained in Example 5 in a manner as described in Example 6 was measured as follows. 0.1 M glucose as a substrate, 2 mM NADP as a coenzyme, and the enzyme were added to a 1 M Tris HCl buffer (pH 8.0), and an increase in absorption at a wavelength of 340 nm was measured at 25°C. Under these reaction conditions, reduction of 1 μ mol NADP into NADPH in one minute was defined as one unit of enzyme activity. The CR enzyme activity was also measured as in Example 5. The thus-measured CR enzyme activity and GDH enzyme activity in the cell-free extract were represented as specific activities and compared with those of *E. coli* HB101 (pNTCR) and a

transformant HB101 (pUCNT) using only a vector. The results are shown in Table 2 below.

Table 2 Simultaneous Expression of CR enzyme and GDH in Recombinant E. coli

Microorganism	CR enzyme specific activity (U/mg)	GDH specific activity (U/mg)
HB101 (pUCNT)	0.12	<0.01
HB101 (pNTCR)	3.76	<0.01
HB101 (pNTCRG)	2.16	87.8

As is seen from Table 2, E. coli HB101 (pNTCRG) exhibited a definite increase in CR enzyme activity and GDH activity in comparison with E. coli HB101(pUCNT) which was transformed using only a vector plasmid.

(Example 8: Synthesis of tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate from tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate using Recombinant E. coli having CR Enzyme Gene introduced therein)

The recombinant E. coli HB101 (pNTCR) obtained in Example 5 was inoculated in 50 ml of 2xYT medium (Bacto tripton 1.6% (w/v), Bacto yeast extract 1.0% (w/v), NaCl 0.5% (w/v), pH 7.0) sterilized in a 500 ml Sakaguchi flask, and cultured with shaking at 37°C for 16 hours. 680 units of GDH (manufactured by Amano Pharmaceutical Co., Ltd.), 5.0 g of glucose, 3.0 mg of NADP, and 4.5 g of tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate were added to 25 ml of the resultant culture. The culture was stirred at 30°C for 40 hours while being adjusted at pH 6.5 with a 5 M aqueous sodium hydroxide solution. After the reaction, the reaction solution was subjected to extraction using ethyl acetate, and an extract after solvent removal was analyzed. As a result, it was found that tert-butyl (3R,5S)-6-

chloro-3,5-dihydroxyhexanoate was produced at a yield of 96.9%. The diastereomer excess ratio of tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate was 98.2% de.

5 Quantification of tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate and tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate, and measurement of the diastereomer ratio of tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate were performed by high performance
10 liquid chromatography (column: COSMOSIL 5CN-R (ID 4.6 x 250 mm) manufactured by Nacalai Tesque Co., Ltd., eluant: 1 mM phosphate solution/acetonitrile = 5/1, flow rate: 0.7 ml/min, detection: 210 nm, column temperature: 30°C).

15 (Example 9: Synthesis of tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate from tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate using Recombinant E. coli with CR Enzyme and GDH Expressed Simultaneously)

 The recombinant E. coli HB101 (pNTCRG) obtained in
20 Example 4 was inoculated in 100 ml of 2xYT medium (Bacto tripton 1.6% (w/v), Bacto yeast extract 1.0% (w/v), NaCl 0.5% (w/v), pH 7.0) sterilized in a 500 ml Sakaguchi flask, and cultured with shaking at 37°C for 16 hours. 5.0 g of glucose, 1.5 mg of NADP, and 5.0 g of tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate were added to 25 ml of the
25 resultant culture. The culture was stirred at 30°C for 24 hours while being adjusted to pH 6.5 with a 5 M aqueous sodium hydroxide solution. After the reaction, the reaction solution was subjected to extraction using ethyl
30 acetate, and an extract after solvent removal was analyzed. As a result, it was found that tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate was produced at a yield of 97.2%. The diastereomer excess ratio of tert-butyl

(3R,5S)-6-chloro-3,5-dihydroxyhexanoate was 98.5% de.

INDUSTRIAL APPLICABILITY

5 It is possible to clone genes of polypeptides having
the enzyme activity to asymmetrically reduce tert-butyl
(S)-6-chloro-5-hydroxy-3-oxohexanoate to tert-butyl
(3R,5S)-6-chloro-3,5-dihydroxyhexanoate, and obtain
transformants having a high level of capability to produce
10 the polypeptides by analyzing the nucleotide sequences of
the genes. Further, it is possible to obtain transformants
capable of producing the polypeptides and glucose
dehydrogenase simultaneously to a large extent.
Furthermore, it is possible to synthesize tert-butyl
15 (3R,5S)-6-chloro-3,5-dihydroxyhexanoate from tert-butyl
(S)-6-chloro-5-hydroxy-3-oxohexanoate using the
transformants.

CLAIMS

1. A polypeptide having an enzyme activity to asymmetrically reduce tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate, wherein the polypeptide comprises the amino acid sequence represented by SEQ ID NO. 1 in the Sequence Listing, or the amino acid sequence having at least one amino acid substitution, insertion, deletion, or addition thereof.
2. A polypeptide according to claim 1, wherein the peptide is derived from a microorganism belonging to genus *Candida*.
3. A polypeptide according to claim 2, wherein the microorganism is *Candida magnoliae* IFO 0705.
4. A polynucleotide encoding a polypeptide according to any one of claims 1 through 3.
5. A polynucleotide encoding a polypeptide having an enzyme activity to asymmetrically reduce tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate to tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate, wherein the polynucleotide is hybridized with a nucleotide sequence represented by SEQ ID NO. 2 in the Sequence Listing under stringent conditions.
6. An expression vector including a polynucleotide according to claims 4 or 5.
7. An expression vector according to claim 6, wherein the expression vector is plasmid pNTCR.

8. An expression vector according to claim 6, further including a polynucleotide encoding a polypeptide having a glucose dehydrogenase activity.

5

9. An expression vector according to claim 8, the polypeptide having a glucose dehydrogenase activity is a glucose dehydrogenase derived from *Bacillus megaterium*.

10

10. An expression vector according to claim 9, wherein the expression vector is plasmid pNTCRG.

15

11. A transformant obtained by transforming a host cell using an expression vector according to any one of claims 6 through 10.

12. A transformant according to claim 11, wherein the host cell is *Escherichia coli*.

20

13. A transformant according to claim 12, wherein the transformant is *E. coli* HB101 (pNTCR).

14. A transformant according to claim 12, wherein the transformant is *E. coli* HB101 (pNTCRG).

25

15. A method for producing tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate, comprising the steps of reacting a transformant according to any one of claims 11 through 14 or a processed product thereof with tert-butyl (S)-6-chloro-5-hydroxy-3-oxohexanoate, and collecting produced tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate.

30

16. A method according to claim 15, wherein the reacting step is carried out in the presence of a coenzyme restoring system.

FIG.1

10 20 30 40 50 60
 GCATGCACGCTACGAAGTGTGCTTACAGATGTCACGTAAGTGTGCATGTGCGTTGCGTGT
 70 80 90 100 110 120
 GCGTTGCGTGTGTGTTGTGGGAATATAAAAGGGCGCAGTTGACTTGACTCGAGACTGTGC
 130 140 150 160 170 180
 ACTAACCTACACCAAAGCTACAAAGATGTCGACTCCGTTGAATGCTCTCGTAACTGGCGC
 M S T P L N A L V T G A
 190 200 210 220 230 240
 TAGCCGCGGCATTGGCGCTGCTACTGCCATTAAAGCTCGCCGAGAATGGATACAGTGTGAC
 S R G I G A A T A I K L A E N G Y S V T
 250 260 270 280 290 300
 GCTGGCTGCGCGTAATGTCGCGAAGCTGAACGAAGTGAAGGAGAAGCTGCCTGTGGTCAA
 L A A R N V A K L N E V K E K L P V V K
 310 320 330 340 350 360
 GGACGGCCAGAAGCACCATCTGGGAGCTCGATCTTGCGAGCGTTGAGGCTGCATCGTC
 D G Q K H H I W E L D L A S V E A A S S
 370 380 390 400 410 420
 CTTCAAGGGCGCGCCTTTACCGGCTAGCGACTACGATCTGTTTCGTTTCGAATGCTGGCAT
 F K G A P L P A S D Y D L F V S N A G I
 430 440 450 460 470 480
 TGCGCAGTTCACGCCAACGGCGGACCAACCGACAAGGACTTCCTGAACATTCTCACCGT
 A O F T P T A D O T D K D F L N I L T V
 490 500 510 520 530 540
 GAACCTCTCCTCCCCCATTTGCGCTCACGAAGGCCCTACTGAAGGGCGTCTCCGAGAGGTC
 N L S S P I A L T K A L L K G V S E R S
 550 560 570 580 590 600
 GAACGAGAAGCCGTTCCATATTATCTTCTCTCGTCCGCTGCAGCCCTGCACGGAGTCCC
 N E K P F H I I F L S S A A A L H G V P
 610 620 630 640 650 660
 TCAGACTGCAGTCTACAGTGCTTCGAAGGGCGGGGCTTGACGGTTTCGTGCGCTCTCTTGC
 Q T A V Y S A S K A G L D G F V R S L A
 670 680 690 700 710 720
 TCGCGAGGTGGGTCCGAAGGGCATTTCATGTGAACGTTATTCATCCTGGTTGGACGAAGAC
 R E V G P K G I H V N V I H P G W T K T
 730 740 750 760 770 780
 TGACATGACGGATGGTATTGACGACCCCAATGATACTCCTATCAAGGGCTGGATCCAGCC
 D M T D G I D D P N D T P I K G W I Q P
 790 800 810 820 830 840
 TGAGGCGATTGCTGATGCGGTTGTGTTCTGGCAAAGTGAAGAACATCACAGGCACTAA
 E A I A D A V V F L A K S K N I T G T N
 850 860 870 880 890 900
 TATCGTGGTGGACAATGGCTTGCTCGCTTGAGTAGATAGAACGGTTTTACGCAATGTTGT
 I V V D N G L L A *
 910 920 930 940 950 960
 TATTACACTTATCGGCAAGGAAACTGCTTTTATGGAGCATGGCCTAGTGTATTGAAACTC
 970 980 990 1000 1010
 CAAAATTAATTAGAGCATACAACACATGGCACCACCGAATTC

FIG. 2

